- A
ArchiMed
- Denis Ribon
Denis Ribon is the current Chairman & Managing Partner at ArchiMed. Denis has also previously served as a Board Director for Provepharm Life Solutions and Citieffe Holding.
Ribon began their career working for Prollenium, a company specializing in advanced medical devices. Denis then transitioned to SUANFARMA, a pharmaceutical company focused on developing new drugs and treatments. After several years with SUANFARMA, Denis moved to ImaBiotech, a diagnostics company that provides personalized medicine solutions.
In 2010, Denis became the CEO of NAMSA, a global contract research organization. Denis then joined ActiGraph as the President & CEO in 2012. In 2014, Denis became a Board Director for Polyplus-transfection S.A. and Citieffe Holding. Denis returned to ArchiMed in 2018 as the Chairman & Managing Partner.
Denis Ribon attended VetAgro Sup, where they studied Veterinary, and then HEC Paris for their Master of Business Administration (MBA). Denis also has a Baccalauréat in Mathematics from Sainte-Marie Lyon.
André - Michel Ballester - Managing Partner, Justin Bateman - Partner, and Christoph Böhmer - Operating Partner report to Denis Ribon.
Org chart
Teams
Offices
This person is not in any offices
ArchiMed
ArchiMed is an independent investment firm specialized in the Healthcare industries. It is a strategic and financial partner to European and North American companies operating in the Biopharma, Medtech, Diagnostics, Life Sciences, Healthcare IT, Consumer Health, Public Safety and Care Services sectors. ArchiMed’s international team combines investment, medical, technological and operational experience. It works alongside management teams to accelerate their business growth, through internationalization, product and service range expansion as well as capacity extension, both organically and through acquisitions. Over the last 20 years, ArchiMed’s leadership team directly managed and invested in over 40 small, medium and large size healthcare companies throughout the world, with a combined value above five billion euros. ArchiMed’s investment capacity currently exceeds one billion euros and potentially twice this amount when including its strategic investment partners.
